Genomic Characterization of Primary Invasive Lobular Breast Cancer

Journal of Clinical Oncology

Volumn 34, Issue 16, 2016, Pages 1872-1880

  Desmedt, Christine ^a   Zoppoli, Gabriele ^a,e   Gundem, Gunes ^h   Pruneri, Giancarlo ^f   Larsimont, Denis ^a   Fornili, Marco ^g   Fumagalli, Debora ^a   Brown, David ^a   Rothé, Françoise ^a   Vincent, Delphine ^a   Kheddoumi, Naima ^a   Rouas, Ghizlane ^a   Majjaj, Samira ^a   Brohée, Sylvain ^a   Van Loo, Peter ^c,i   Maisonneuve, Patrick ^f   Salgado, Roberto ^a   Van Brussel, Thomas ^d   Lambrechts, Diether ^d   Bose, Ron ^j   Metzger, Otto ^k   Galant, Christine ^b   Bertucci, François ^l   Piccart Gebhart, Martine ^a   Viale, Giuseppe ^f   Biganzoli, Elia ^g   Campbell, Peter J ^h   Sotiriou, Christos ^a   more..

^a JULES BORDET INSTITUTE   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e UNIVERSITY OF GENOA   (Italy)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

ⁱ THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^j WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l INSTITUT PAOLI CALMETTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; TRANSCRIPTION FACTOR RUNX1; UVOMORULIN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN;

ADULT; AGED; AKT1 GENE; BREAST CANCER; CANCER GENETICS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CDH1 GENE; CHROMOSOME 11P; CHROMOSOME 1Q; CONFERENCE PAPER; CONTROLLED STUDY; COPY NUMBER VARIATION; ESR1 GENE; FOXA1 GENE; GENE EXPRESSION; GENOMICS; HER2 GENE; HER3 GENE; HISTOPATHOLOGY; HUMAN; INDEL MUTATION; INVASIVE LOBULAR BREAST CANCER; KMT2C GENE; MAJOR CLINICAL STUDY; MAP3K1 GENE; MIDDLE AGED; MUTATION RATE; P53 GENE; PIK3CA GENE; PRIMARY TUMOR; PRIORITY JOURNAL; PTEN GENE; RUNX1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL ANALYSIS; TBX3 GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE; BREAST TUMOR; FEMALE; GENETICS; LUNG CARCINOMA; MORTALITY; MUTATION; PATHOLOGY;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, LOBULAR; DNA COPY NUMBER VARIATIONS; FEMALE; GENOMICS; HUMANS; MIDDLE AGED; MUTATION; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

EID: 84974539687     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.0334     Document Type: Conference Paper

References (34)

1. Lakhani SR, Schnitt EI, Hoon Tan SJ, et al: WHO Classification of Tumors of the Breast (ed 4). Lyon, France IARC, 2012
2. Iorfida M, Maiorano E, Orvieto E, et al: Invasive lobular breast cancer: Subtypes and outcome. Breast Cancer Res Treat 133:713-723, 2012
3. Guiu S, Wolfer A, Jacot W, et al: Invasive lobular breast cancer and its variants: How special are they for systemic therapy decisions? Crit Rev Oncol Hematol 92:235-257, 2014
4. Metzger O, Giobbie-Hurder A, Mallon E, et al: Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. Cancer Res 72:S1-1, 2012 (abstr)
5. Knauer M, Gruber C, Dietze O, et al: Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 study. Cancer Res 75:S2-06, 2015 (abstr)
6. Goncalves R, Warner WA, Luo J, et al: New concepts in breast cancer genomics and genetics. Breast Cancer Res 16:460, 2014
7. Carter SL, Cibulskis K, Helman E, et al: Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 30:413-421, 2012
8. Varela I, Tarpey P, Raine K, et al: Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469:539-542, 2011
9. Ye K, Schulz MH, Long Q, et al: Pindel: A pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25: 2865-2871, 2009
10. Desmedt C, Fumagalli D, Pietri E, et al: Uncovering the genomic heterogeneity of multifocal breast cancer. J Pathol 236:457-466, 2015
11. Metzger-Filho O, Michiels S, Bertucci F, et al: Genomic grade adds prognostic value in invasive lobular carcinoma. Ann Oncol 24:377-384, 2013
12. Hudis CA, Barlow WE, Costantino JP, et al: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol 25:2127-2132, 2007
13. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68:6084-6091, 2008
14. Liu Z, Merkurjev D, Yang F, et al: Enhancer activation requires trans-recruitment of a mega transcription factor complex. Cell 159:358-373, 2014
15. Gonzalez-Perez A, Jene-Sanz A, Lopez-Bigas N: The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. Genome Biol 14:r106, 2013
16. Bose R, Kavuri SM, Searleman AC, et al: Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3:224-237, 2013
17. Collier TS, Diraviyam K, Monsey J, et al: Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface. J Biol Chem 288:25254-25264, 2013
18. Jaiswal BS, Kljavin NM, Stawiski EW, et al: Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23:603-617, 2013
19. Jaiswal B.S. , KljavinN.M., StawiskiE.W., et al: Erratum: Oncogenic ERBB3 Mutations in Human Cancers Cancer Cell 25:543-544, 2014
20. Littlefield P, Liu L, Mysore V, et al: Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Sci Signal 7:ra114, 2014
21. U M, Talevich E, Katiyar S, et al: Prediction and prioritization of rare oncogenic mutations in the cancer kinome using novel features and multiple classifiers. PLOS Comput Biol 10:e1003545, 2014
22. Wu JY, Yu CJ, Chang YC, et al: Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 17:3812-3821, 2011
23. Desmedt C, Haibe-Kains B, Wirapati P, et al: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158-5165, 2008
24. Robinson JL, Holmes KA, Carroll JS: FOXA1 mutations in hormone-dependent cancers. Front Oncol 3:20, 2013
25. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490:61-70, 2012
26. Coniglio SJ, Zavarella S, Symons MH: Pak1 and Pak2 mediate tumor cell invasion through distinct signaling mechanisms. Mol Cell Biol 28:4162-4172, 2008
27. Peres J, Prince S: The T-box transcription factor, TBX3, is sufficient to promote melanoma formation and invasion. Mol Cancer 12:117, 2013
28. Tamura M, Gu J, Matsumoto K, et al: Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280:1614-1617, 1998
29. Ciriello G, Gatza ML, Beck AH, et al: Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163:506-519, 2015
30. Chmielecki J, Ross JS, Wang K, et al: Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist 20:7-12, 2015
31. Fang Y, Jiang Y, Wang X, et al: Somatic mutations of the HER2 in metastatic breast cancer. Tumour Biol 35:11851-11854, 2014
32. Ross JS, Wang K, Sheehan CE, et al: Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res 19:2668-2676, 2013
33. Lien HC, Chen YL, Juang YL, et al: Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast. Breast Cancer Res Treat 150:447-455, 2015
34. Li S, Shen D, Shao J, et al: Endocrine-therapyresistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Reports 4:1116-1130, 2013